Cost effectiveness of fulvestrant as an additional endocrine step in the treatment sequence for hormone responsive advanced breast cancer

被引：0
|
作者：
Hirsch, M. W.
Gait, C.
Chambers, J.
机构：
[1] AstraZeneca UK Ltd, Macclesfield, Cheshire, England
[2] Mapi Values Ltd, Macclesfield, Cheshire, England
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63472-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A288 / A288
页数：1
相关论文
共 50 条
  • [41] Standard of Care and Controversies in the Adjuvant Endocrine Treatment of Hormone-Responsive Early Breast Cancer
    Bauerschlag, Dirk O.
    Maass, Nicolai
    Schem, Christian
    BREAST CARE, 2014, 9 (04) : 283 - 286
  • [42] Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.
    Mrozek, E.
    Schaaf, L. J.
    Ramaswamy, B.
    Shiels, D.
    Houton, L.
    Shapiro, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 387S - 387S
  • [43] Therapeutic strategies for the treatment of endocrine resistant hormone receptor positive advanced breast cancer
    Grellety, Thomas
    Hajjaji, Nawale
    Petit, Thierry
    Bailleux, Caroline
    BULLETIN DU CANCER, 2023, 110 (01) : 69 - 87
  • [44] Endocrine agents in the treatment of advanced breast cancer
    Bauerfeind, I
    Untch, M
    GYNAKOLOGE, 1999, 32 (08): : 605 - 613
  • [45] Endocrine treatment of advanced breast cancer - Introduction
    Howell, T
    BRITISH JOURNAL OF CANCER, 2004, 90 : S1 - S1
  • [46] Fulvestrant: Pharmacologic profile versus existing endocrine agents for the treatment of breast cancer
    Buzdar, Aman U.
    Robertson, John F. R.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (09) : 1572 - 1583
  • [47] First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis
    Huang, Xiaoting
    Lin, Shen
    Rao, Xin
    Zeng, Dayong
    Wang, Hang
    Weng, Xiuhua
    Huang, Pinfang
    CLINICAL BREAST CANCER, 2021, 21 (04) : E479 - E488
  • [48] FULVESTRANT ('FASLODEX'): A NEW OPTION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
    Kleeberg, Ulrich R.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3537 - 3537
  • [49] Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
    I. Blancas
    M. Fontanillas
    V. Conde
    J. Lao
    E. Martínez
    M. J. Sotelo
    A. Jaen
    J. L. Bayo
    F. Carabantes
    J. J. Illarramendi
    M. M. Gordon
    J. Cruz
    A. García-Palomo
    C. Mendiola
    E. Pérez-Ruiz
    J. S. Bofill
    J. M. Baena-Cañada
    N. M. Jáñez
    G. Esquerdo
    M. Ruiz-Borrego
    Clinical and Translational Oncology, 2018, 20 : 1631 - 1632
  • [50] Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre
    Cheung, KL
    Owers, R
    Robertson, JFR
    ENDOCRINE-RELATED CANCER, 2006, 13 (01) : 251 - 255
12345